期刊文献+

可诱导共刺激分子在系统性红斑狼疮病人外周血T细胞亚群的表达及与临床的关系 被引量:4

Expression and clinical significance of inducible co-stimulator on peripheral blood T lymphocyte subsets in patients with systemic lupus erythematosus
原文传递
导出
摘要 目的 检测可诱导共刺激分子(inducibleco stimulator,ICOS)及相关免疫分子在SLE病人外周血T细胞亚群的表达,探索其与SLE疾病活动程度、病程及血清抗dsDNA抗体和免疫球蛋白含量间的关系,为进一步研究ICOS在SLE免疫病理中的作用奠定基础。方法 采用流式细胞术检测第二军医大学附属长海医院住院和门诊SLE患者 (n=51)以及健康体检者 (n=30)外周血T细胞亚群表面ICOS及其他免疫分子CD45RO、CD45RA、HLA DR的表达水平,观察ICOS在不同细胞亚群表达水平与SLE活动程度、病程、血清抗dsDNA抗体和血清免疫球蛋白含量间的关系。结果 与正常人相比,活动期及稳定期SLE患者外周血CD4+T细胞、CD8+T细胞表达ICOS的水平显著升高,但活动期患者与稳定期患者之间无统计学差异(P≥0 05);同一SLE患者在疾病活动期,外周血CD4+、CD8+、CD45RO+、CD4+CD45RO+和CD8+CD45RO+细胞表面ICOS的表达水平明显高于该患者经过治疗疾病缓解阶段(P<0 05);初发SLE患者CD45RO+细胞表达ICOS水平明显高于复发患者 (P<0 05);血清抗dsDNA抗体( +)及免疫球蛋白(IgG、IgM和IgA中任何一种 )异常升高的患者外周血CD45RO+及CD4+CD45RO+细胞表达ICOS的水平分别明显高于血清抗dsDNA抗体 ( -)和免疫球蛋白含量正常的患者(P<0 05)。 Objective To investigate the expression of inducible co stimulator (ICOS) and other immunological molecules on peripheral blood T lymphocyte subsets in patients with systemic lupus erythematosus (SLE) and to find out the relationship with disease activity, disease stage and the contents of anti dsDNA antibody and immunoglobulin in serum so as to pave the way for further studying the possibly immunologically pathological role of ICOS in SLE. Methods Peripheral blood samples were collected from 51 patients with SLE, 3 males and 22 females. Three color flow cytometry was used to detect the levels of ICOS, CD45RO, CD45RA, and HLA DR expression on the peripheral blood T lymphocytes subsets. The results were analyzed along with the disease activity, disease stage, contents of anti dsDNA antibody and immunoglobulin in serum. Thirty healthy subjects were used as controls.Results Compared with the healthy subjects the level of ICOS expression on the peripheral blood CD4 + and CD8 + T cells in the patients with SLE during active and stable stages were significantly increased (all P <0.05), but there was no significant difference between the last two group patients ( P ≥0.05); In the same patients, the level of ICOS expression on the peripheral blood CD4 + , CD8 + , CD45RO +、CD4 +CD45RO +and CD8 +CD45RO + cells in active stage were significantly increased compared with those in stable stage ( P <0 05); The level of ICOS expression on the peripheral blood CD45RO + cells in the untreated primary patients was higher than those with disease relapse ( P <0 05); The levels of ICOS expression on the peripheral blood CD45RO + and CD4 +CD45RO + cells were significantly increased in the patients with serum anti dsDNA antibody (+) and the patients with aberrantly high content of immunoglobulin compared with those of the patients with serum anti dsDNA antibody (-) and the patients with normal content of immunoglobulin, respectively (all P <0 05). Conclusion ICOS is aberrantly highly expressed on certain peripheral blood T lymphocyte subsets in patients with SLE, which is related to disease activity, disease stage and the contents of serum anti dsDNA antibody and immunoglobulin, thus ICOS may play a role in SLE pathogenesis.
出处 《中华医学杂志》 CAS CSCD 北大核心 2005年第5期318-323,共6页 National Medical Journal of China
基金 国家"863"高技术研究发展计划基金资助 (2002AA214091 ) 上海市科委自然科学基金资助(03ZR14026)
关键词 ICOS SLE 患者 CD45RO 抗DSDNA抗体 T细胞亚群 外周血 水平 活动 结论 Lupus erythematosus, systemic T-lymphocytes Inducible co-stimulator
  • 相关文献

参考文献22

  • 1Bijl M, Horst G, Limburg PC, et al. Expression of costimulatory molecules on peripheral blood lympnocytes of patients with systemic lupus erythematosus. Ann Rheum Dis,2001,60:523-526.
  • 2Abe K, Takasaki Y, Ushiyama C, et al. Expression of CD80 and CD86 on peripheral blood T lymphocytes in patients with systemic lupus erythematosus. T Clin Immunol, 1999, 19:58-66.
  • 3Lin MF, Li JS, Weng TH, et al. Differential expression and modulation of costimulatory molecules CD80 and CD86 on monocytes from patients with systemic lupus erythematosus. Scand J Immunol,1999, 49:82-87.
  • 4Yellin MJ, Thienel U. T cells in the pathogenesis of systemic lupus erythematosus: potential roles of CD154-CD40 interactions and costimulatory molecules. Curr Rheumatol Rep, 2000, 2:24-31.
  • 5Wang XB, Huang W, Mihara M, et al. Mechansim of action of combined short-term CTLA 4 Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J Immunol, 2002,168:2046-2053.
  • 6Tafurl A, Shahinian A, Bladt F, et al. ICOS is essential for effective T-helper-cell responses. Nature, 2001,409:105-109.
  • 7McAdam AJ, Greenwaald RJ, Levin MA, et al. ICOS is critical for CD40-mediated antibody class switching. Nature,2001,409:102-105.
  • 8Khayyamian S, Hutloff A, Büchner K, et al. ICOS-ligand, expressed on human endothelial cells, costimulates Th1 and Th2 cytokine secretion by memory T cell. Proc Natl Acad Sci U S A,2002,99: 6198-6203.
  • 9Nurieva RI, Mai XM, Forbush K, et al. B7h is required for T cell activation, differentiation, and effector function. Proc Natl Acad Sci U S A,2003,100:14163-14168.
  • 10Nanji SA, Hancock WW, Anderson CC,et al. Combination therapy with anti-ICOS and cyclosporine enhances cardiac but not islet allograft survival. Transplant Proc, 2003, 35:2477-2478.

同被引文献72

  • 1穆荣,戴振鹏,栗占国,高晓明.T细胞疫苗治疗系统性红斑狼疮的初步临床研究[J].中华内科杂志,2004,43(8):568-571. 被引量:7
  • 2陈志平,刘贞富,郑舜华,梁智辉.可诱导共刺激分子在系统性红斑狼疮患者外周血T淋巴细胞的表达[J].中华皮肤科杂志,2005,38(1):8-10. 被引量:4
  • 3金永柱,王光明,李爱玲,谢蜀生.腺病毒介导CTLA4-FasL基因转移诱导大鼠心脏移植物长期存活的作用[J].中华医学杂志,2003,83(22):1968-1974. 被引量:11
  • 4Hoffman RW. T cells in the pathogenesis of systemic lupus erythematosus. Clin Immunol, 2004, 113: 4-13.
  • 5Yasutomo K. Pathological lymphocyte activation by defective clearance of self-ligands in systemic lupus erythematosus. Rheumatology (Oxford), 2003, 42: 214-222.
  • 6Alvarado-Sanchez B, Hemandez-Castro B, Portales-Perez D, et al. Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun, 2006, 27: 110-118.
  • 7Park Y, Lee SK, Kim DS, et al. Elevated IL-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol, 1998, 16: 283-288.
  • 8Llorente L, Richand-Patin Y, Garcia-Padilla C, et al. Clinical and biologic effects of anti-interleukin 10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum, 2000, 43: 1790-1800.
  • 9Tackey E, Lipsky PE, Illei G. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus, 2004, 13: 339- 343.
  • 10Belmont HM, Buyon J, Giorno R, et al. Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus: The Shwartzman phenomenon revisited. Arthritis Rheum, 1994, 37: 376-383.

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部